Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.75 |
| ▸ | VCP | P55072 | 1/20 | 0.66 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28695966 | 1.00 | APP (0.75) | APPVCPMAOAMAOBNPC1 | |
| SCHEMBL10069794 | 0.93 | APP (0.84) | APPVCPNPC1RAB9ACES2 | |
| SCHEMBL25749196 | 0.88 | VCP (0.82) | APPVCPCES2CES1 | |
| SCHEMBL29869041 | 0.87 | APP (0.58) | APPVCPMAOAMAOBNPC1 | |
| SCHEMBL21679451 | 0.87 | APP (0.58) | APPVCPMAOAMAOBNPC1 | |
| SCHEMBL28972914 | 0.86 | APP (0.73) | APPVCPRAB9ACES2CES1 | |
| SCHEMBL28972932 | 0.86 | APP (0.64) | APPVCPNPC1RAB9ACES2 | |
| SCHEMBL28629549 | 0.86 | APP (0.73) | APPVCPCES2CES1 | |
| SCHEMBL28972824 | 0.86 | APP (0.73) | APPVCPMAOAMAOBNPC1 | |
| SCHEMBL10170737 | 0.86 | APP (0.73) | APPVCPCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186408-A1 | TREATMENT OF PHARMACORESISTANT EPILEPSY | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-06-12 | — | — | US | disclosed |
| EP-4333819-A1 | TREATMENT OF PHARMACORESISTANT EPILEPSY | Katholieke Universiteit Leuven (BE) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022233877-A1 | TREATMENT OF PHARMACORESISTANT EPILEPSY | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-11-10 | — | — | WO | disclosed |
| CN-113429280-B | Method for preparing chalcone compounds by selective hydrogenation reduction of alkynone under catalysis of Ti (III) complex | 陕西师范大学 | 2022-08-23 | — | — | CN | disclosed |
| CN-113429280-A | Method for preparing chalcone compounds by selective hydrogenation reduction of alkynone under catalysis of Ti (III) complex | 陕西师范大学 | 2021-09-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186408-A1 | TREATMENT OF PHARMACORESISTANT EPILEPSY | CNR1, CNR2, CYP2J2 | APP 1233/4885VCP 4323/4885MAOA 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.